TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patients across 32 sites, demonstrated a 10% overall response rate in monotherapy and 13% in combination therapy.
Notable results included a 21% response rate in platinum-resistant ovarian cancer (PROC) patients and 33.3% in mucosal melanoma patients.
The treatment was generally well-tolerated with manageable side effects.
Data readouts from two ongoing registrational trials are expected in Q1/Q2
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment